Navigation Links
Prime Therapeutics Receives VIPPS Accreditation

ST. PAUL, Minn., May 21 /PRNewswire/ -- Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, announced today that it has received accreditation from the National Association of Boards of Pharmacy(R) (NABP(R)) through its Verified Internet Pharmacy Practice Sites(TM) (VIPPS(R)) Program.

Prime has met the VIPPS standards established by NABP in response to consumers' concerns regarding the safety of pharmacy practices on the Internet. VIPPS accreditation further authenticates Prime's Web-based pharmacy services as a reputable, accredited source of prescription drugs. PrimeMail(R), Prime's mail-service pharmacy, uses the Internet as a safe and convenient way for members to place orders and provides access to a number of useful pharmacy tools.

"Prime's top priority is ensuring that clients and members are continually receiving the highest quality care and service," said Keith McFalls, Vice President of PrimeMail. "VIPPS accreditation further demonstrates Prime's commitment to providing unmatched member safety and satisfaction while empowering clients with tools and information to aid in making more informed health care management decisions."

To become VIPPS accredited, a pharmacy must comply with the licensing and inspection requirements in each state they dispense pharmaceuticals. In addition, pharmacies that are VIPPS accredited have demonstrated to NABP compliance with VIPPS criteria, including: patient rights to privacy, authentication and security of prescription orders, adherence to a recognized quality assurance policy, and provision of meaningful consultation between patients and pharmacists.

Prime began the VIPPS accreditation process in April 2007 and received official accreditation confirmation on March 5, 2008. Prime's Web services provide a wide range of pharmacy benefit information and protects member confidentiality with password protections, encryption, firewalls and secure links. Member Web sites also include useful tools such as drug research options that allow members to review specific drug information, a complete prescription history list and a cost calculator that offers side by side cost comparisons of brand-name and generic drugs at both PrimeMail and retail pharmacies.

Prime Therapeutics is a pharmacy benefit management company dedicated to providing, innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 (legal) million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by ten Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at

NABP is the independent, international, and impartial Association that assists its member boards and jurisdictions in developing, implementing, and enforcing uniform standards for the purpose of protecting the public health.

SOURCE Prime Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Primera Biosystems Raises $21 Million in Series B Private Round
2. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
3. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
4. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Nile Therapeutics Reports 2008 First Quarter Financial Results
6. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
7. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
8. Amicus Therapeutics Announces First Quarter 2008 Financial Results
9. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
11. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider ... , today announced that the company has set a new ... 391% quarter on quarter growth posted for Q3 of 2014 to ... and Mexico , with the establishment of an ... 2015. --> United Kingdom and ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... 17 au 19 novembre  2015.  --> Paris ... 2015.  --> DERMALOG, le leader de l,innovation ... à la fois passeports et empreintes sur la même ... pour les passeports et l,autre pour les empreintes digitales. ...
(Date:11/12/2015)... 2015  A golden retriever that stayed healthy despite ... has provided a new lead for treating this muscle-wasting ... Institute of MIT and Harvard and the University of ... Cell, pinpoints a protective gene that ... effects. The Boston Children,s lab of Lou Kunkel ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):